Amgen's Denosumab Trumps Zometa with Top-Line Results for Cancer Bone Complications
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen has great expectations for denosumab, but the drug still has a long road ahead and an upcoming FDA Advisory Committee review before it hits the market.